Scientific Advisors

Shibo Jiang, MD
Co-founder & Scientific Advisor

"National Talent" Program Scholar (2010-now); Director at the Institute of Medical Microbiology, Fudan University; Professor, Shanghai Medical College; Fellow of the American Academy of Microbiology.

Lab Head and Member (1990-2010) at the Lindsley F. Kimball Research Institute of the New York Blood Center, New York, USA;

In the early 90s, discovered the 1st highly potent anti-HIV C-peptide and the patent was licensed to Trimeris Pharmaceuticals for the development of the world's first anti-HIV peptide drug, enfuvirtide (Fuzeon, also known as T-20) with annual sales of $100~200 millions;

In the early 2010s, discovered that the 3-hydroxyphthalicanhydride-modified bovine β-lactoglobulin (3HP-β-LG) could effectively inhibit human papillomavirus (HPV) infection and the patent was licensed to Jinbo Bio-pharmaceutical Co., Ltd for the development of "anti-HPV bioprotein dressing", which was approved by CFDA and has been used in more than 1,300 hospitals nationwide by more than 400,000 HPV-infected patients;

In 2016, discovered the 1st peptide-based pan-CoV entry inhibitor, EK1, that is effective against all the highly pathogenic human coronaviruses tested, including SARS-CoV, MERS-CoV, SARS-CoV-2 and its variants. EK1 inhaler for treatment of COVID-19 patients is now in phase II clinical trials.

In the early 2020s, discovered the 1st STING agonist-based pan-sarbecovirus vaccine that elicits potent immune responses against SARS-CoV, SARS-CoV-2 and its variants. The patent was licensed to BravoVax Co., Ltd for the development of a broad-spectrum vaccine for prevention of infection by SARS-CoV-2 and its variants.   

Applied for more than 110 U.S., Chinese and PCT patents (54 issued), of which 11 patents have been successfully licensed out. Published >580 scientific papers in high-profile journals (e.g., Cell, Nature, Science, Lancet) with more than 43,000 citations and h-index of 102.